Brightsurf Science News & Current Events

December 08, 2012
Researchers develop novel 3-D culture system for inflammatory breast cancer
Inflammatory breast cancer is a very rare and aggressive disease.

Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology.

Investigational agent targets gene signaling pathways to improve response for patients with CLL
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia, according to studies presented today at the 54th Annual Meeting of the American Society of Hematology.

Studies challenge standards to improve treatment outcomes for patients with clotting disorders
Studies presented today at the 54th Annual Meeting of the American Society of Hematology examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Updated results from early phase clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.